#Japan #Tokyo #Leukemia #Curry Fund #Liquid Mine

Investment by Umusan Lab's Curry Fund in Liquid Mine

Umusan Lab has successfully invested in Liquid Mine through its impact investment fund, Curry Impact & Innovation No. 1. This investment aims to support Liquid Mine, a company specializing in genome analysis technology capable of identifying genetic mutations related to blood cancers like leukemia.

Understanding Leukemia: Characteristics and Treatment Challenges
Leukemia is a blood cancer triggered by genetic abnormalities such as mutations. It is categorized into various types, some of which hold a five-year survival rate as low as 10%, making it a critical health concern. Okinawa Prefecture particularly stands out with high rates of both leukemia patients and fatalities, raising significant alarm.

The aggressive treatments for leukemia, including powerful radiation therapy and chemotherapy, can severely impact patients' quality of life (QOL). These treatments often result in side effects such as diminished reproductive health and weakened immune systems, leading to increased susceptibility to infections.

To formulate effective treatment strategies, it is essential to accurately identify the genetic mutations responsible for the disease in each patient. Current testing methods can cover several known genetic mutations linked to the illness. However, they may fail to uncover the mutations in complex cases or when standard treatments do not yield positive results, posing a significant challenge for healthcare.

Liquid Mine's Innovative Solution
Liquid Mine's technology provides a comprehensive analysis of a patient's entire genome, facilitating the examination of known and unknown mutations suspected of influencing the disease. A significant advantage of their approach lies in the ability to generate custom testing reagents based on specific mutations unique to each patient. This tracking component allows for monitoring cancer cell activity and detecting treatment effectiveness, ultimately improving the selection of tailored therapies for each individual while minimizing ineffective treatments and unnecessary side effects.

Moreover, traditional genetic testing for leukemia requires invasive procedures like bone marrow extraction, which can impose considerable physical and psychological strain on patients. Liquid Mine offers a non-invasive alternative through blood tests, thereby easing the burden while ensuring frequent monitoring as needed.

Investment Reasons: Expectations from the Curry Fund
By investing in Liquid Mine, the Curry Fund aims to enhance the precision of treatments for challenging blood cancers like leukemia, thus improving patient survival rates and overall quality of life. Currently, Liquid Mine's technology remains unavailable in Okinawa, but future collaboration with local healthcare institutions could establish a cutting-edge testing environment for patients right in the prefecture.

The Curry Fund will support the realization of Liquid Mine's vision through investment, impact measurement, and management.

Overview of Liquid Mine

• - Name: Liquid Mine, Inc.
• - CEO: Tomokazu Kishimoto
• - Location: 2F-C Shibuya Dogenzaka Tokyu Building, 1-10-8 Dogenzaka, Shibuya, Tokyo
• - Established: November 7, 2019
• - Website: liquidmine.co.jp

Overview of the Curry Fund

• - Name: Curry Impact & Innovation No. 1 Limited Liability Partnership
• - Established: May 10, 2023
• - General Partner: Umusan Lab, Inc.
• - Location: 4-5-25 Naiman, Urasoe, Okinawa
• - Website: karry-fund.jp

Overview of Umusan Lab

• - Name: Umusan Lab, Inc.
• - CEO: Takashi Hiyane
• - Location: 4-5-25 Naiman, Urasoe, Okinawa
• - Founded: January 1, 2019
• - Website: umusunlab.co.jp

Inquiries

For more information, please contact the Curry Fund office at Umusan Lab: [email protected]